Exact Sciences Corporation (NASDAQ:EXAS) – Research analysts at Leerink Swann increased their FY2017 EPS estimates for Exact Sciences Corporation in a report released on Monday. Leerink Swann analyst P. Souda now expects that the medical research company will post earnings of ($1.10) per share for the year, up from their previous estimate of ($1.27). Leerink Swann has a “Outperform” rating and a $63.00 price objective on the stock. Leerink Swann also issued estimates for Exact Sciences Corporation’s Q4 2017 earnings at ($0.29) EPS, Q1 2018 earnings at ($0.26) EPS, Q2 2018 earnings at ($0.21) EPS, Q3 2018 earnings at ($0.14) EPS, Q4 2018 earnings at ($0.09) EPS, FY2018 earnings at ($0.69) EPS and FY2019 earnings at $0.26 EPS.

Several other equities analysts also recently issued reports on EXAS. Vetr downgraded shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating and set a $36.37 price objective on the stock. in a report on Thursday, July 6th. Craig Hallum upped their price objective on Exact Sciences Corporation from $35.00 to $41.00 in a research report on Friday, July 7th. Benchmark Co. set a $50.00 price objective on Exact Sciences Corporation and gave the stock a “buy” rating in a research report on Friday, July 7th. BTIG Research restated a “buy” rating and issued a $45.00 price objective (up previously from $35.00) on shares of Exact Sciences Corporation in a research report on Monday, July 17th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $42.00 target price (up from $38.00) on shares of Exact Sciences Corporation in a research note on Thursday, July 20th. Six analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Exact Sciences Corporation presently has an average rating of “Buy” and an average target price of $49.71.

TRADEMARK VIOLATION WARNING: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/11/02/leerink-swann-research-analysts-lift-earnings-estimates-for-exact-sciences-corporation-exas.html.

Exact Sciences Corporation (NASDAQ:EXAS) last announced its quarterly earnings data on Monday, October 30th. The medical research company reported ($0.23) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.07. Exact Sciences Corporation had a negative net margin of 60.71% and a negative return on equity of 30.32%. The company had revenue of $72.60 million for the quarter, compared to the consensus estimate of $65.03 million. During the same period in the prior year, the firm posted ($0.36) EPS. Exact Sciences Corporation’s revenue for the quarter was up 158.4% on a year-over-year basis.

In other news, insider Graham Peter Lidgard sold 81,025 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total value of $3,821,139.00. Following the completion of the transaction, the insider now directly owns 366,519 shares of the company’s stock, valued at $17,285,036.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP D Scott Coward sold 29,115 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total value of $1,373,063.40. Following the completion of the transaction, the senior vice president now directly owns 64,991 shares of the company’s stock, valued at $3,064,975.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 231,598 shares of company stock worth $10,182,030. 4.00% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Fortaleza Asset Management Inc. acquired a new position in Exact Sciences Corporation in the second quarter valued at $106,000. Krilogy Financial LLC increased its stake in Exact Sciences Corporation by 1,460.0% during the second quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock worth $138,000 after acquiring an additional 3,650 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in Exact Sciences Corporation by 17.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after acquiring an additional 600 shares during the last quarter. Financial Architects Inc increased its stake in Exact Sciences Corporation by 90.0% during the second quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock worth $152,000 after acquiring an additional 2,035 shares during the last quarter. Finally, Johnson Financial Group Inc. increased its stake in Exact Sciences Corporation by 25.9% during the second quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock worth $172,000 after acquiring an additional 1,000 shares during the last quarter. 85.12% of the stock is owned by institutional investors.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Earnings History and Estimates for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.